GEN Exclusives

More »

GEN News Highlights

More »
Feb 21, 2008

Genmab Steps Up Production Capacity through $240M Purchase of PDL BioPharma’s Site

  • Genmab is acquiring PDL BioPharma’s antibody manufacturing facility for $240 million in cash. The transaction includes the plant located in Brooklyn Park, MN, land, equipment, and access to a leased space housing a development lab.

    Genmab expects that the Minnesota site, which has a production capacity of 22,000 liters, will be sufficient to provide a sustainable source of both clinical- and commercial-scale material for its pipeline.

    “The facility includes two 1,000-liter and two 10,000-liter bioreactors, which support the simultaneous manufacture of multiple antibody products and will enable Genmab to transition three antibodies from research to manufacturing per year,” according to Lisa N. Drakeman, Ph.D., CEO of Genmab.



Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Stopping Research Fraud

What is the best approach to curbing scientific misconduct and outright fraud?